ST美晨 reported revenue of ¥0.96B for the period ended 2026-06-30, +11.6% year on year. Net income was ¥-0.04B, a -4.2% net margin on a 13.1% gross margin. The largest revenue line is 汽车配件 at 99% of the total. Free cash flow for the period was ¥0.11B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.96B | +11.6% |
| Gross profit | ¥0.13B | — |
| Operating income | ¥-0.04B | — |
| Net income | ¥-0.04B | — |
| Gross margin | 13.1% | Net margin -4.2% |
| Revenue Q/Q | +0.2% | — |
| Segment | Revenue | Share |
|---|---|---|
| 汽车配件 | ¥0.96B | 99.2% |
| 其他 | ¥0.00B | 0.5% |
| 园林 | ¥0.00B | 0.3% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.84B | 86.9% |
| R&D | ¥0.04B | 4.2% |
| SG&A | ¥0.07B | 7.1% |
| Tax & other | ¥0.00B | 0.1% |
| Item | Amount |
|---|---|
| Total assets | ¥4.23B |
| Total liabilities | ¥4.10B |
| Shareholders' equity | ¥0.13B |
| Equity / assets | 3.2% |
| Operating cash flow | ¥0.11B |
| Capital expenditure | ¥0.00B |
| Free cash flow | ¥0.11B |
| Cash conversion (OCF / net income) | -371% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
冠昊生物 ・ 东宝生物 ・ 飞力达 ・ 瑞丰光电 ・ 佳云科技 ・ 瑞丰高材 ・ 迪安诊断 ・ ST天玑 ・ 宝莱特 ・ 融捷健康 ・ 新开普 ・ 依米康
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies